அடித்தளம் க்கு பால்டிக் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from அடித்தளம் க்கு பால்டிக். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In அடித்தளம் க்கு பால்டிக் Today - Breaking & Trending Today

Modus Therapeutics Appoints Sedermera Fondkommission as Financial Advisor to Support Planned Listing on Nasdaq First North Growth Market

Modus Therapeutics Appoints Sedermera Fondkommission as Financial Advisor to Support Planned Listing on Nasdaq First North Growth Market
- Listing to fund the clinical development of sevuparin for sepsis/septic shock
- No pharmaceutical products are currently available that are specifically meant to treat patients with sepsis/septic shock
News provided by
Share this article
STOCKHOLM, March 15, 2021 /PRNewswire/
Modus Therapeutics Holding AB, a company developing innovative treatments for patients with high unmet medical needs, announces that it has appointed Sedermera Fondkommission as financial adviser to support its planned listing on Nasdaq First North Growth Market. The engagement of Sedermera Fondkommission follows the appointment of Claes Lindblad at Modus Therapeutics as its new Chief Financial Officer. ....

Claes Lindblad , Sedermera Fondkommission , Citigate Dewe Rogerson , Prnewswire Modus Therapeutics Holding , Karolinska Development Ab Nasdaq Stockholm , Karolinska Development , Foundation For Baltic , Nasdaq First North Growth , Modus Therapeutics , Chief Financial , Nasdaq First North Growth Market , Nasdaq Stockholm , Rosetta Capital , European Studies , David Dible , Citigate Dewe , அடித்தளம் க்கு பால்டிக் , நாஸ்டாக் முதல் வடக்கு வளர்ச்சி , மோடஸ் சிகிச்சை , தலைமை நிதி , நாஸ்டாக் முதல் வடக்கு வளர்ச்சி சந்தை , நாஸ்டாக் ஸ்டாக்‌ஹோல்ம் , ரொசெட்டா மூலதனம் , ஐரோப்பிய ஆய்வுகள் , டேவிட் டிபிலே ,

Modus Therapeutics - Claes Lindblad Joins as Chief Financial Officer

Modus Therapeutics
Share this article
STOCKHOLM, March 12, 2021 /PRNewswire/
Modus Therapeutics Holding AB, a company developing innovative treatments for patients with high unmet medical needs, announces that it has appointed Claes Lindblad as its new Chief Financial Officer. He joins the Company as it looks for funding to support the development of sevuparin, into a new important potential treatment for sepsis/septic shock, and other severe inflammatory complications that millions of patients suffer from because of serious medical conditions such as major trauma and surgery, autoimmunity, and viral infection.
In many patients, these severe conditions result in severe uncontrolled systemic inflammation (also known as systemic inflammatory response syndrome, SIRS), which can then progress into shock and multi-organ failure. One example being septic shock, which is a leading cause of death in intensive care units worldwide, with mortality rates typically exceedi ....

United Kingdom , Claes Lindblad , Nycomed Takeda , Citigate Dewe Rogerson , Prnewswire Modus Therapeutics Holding , Karolinska Development Ab Nasdaq Stockholm , Karolinska Development , Foundation For Baltic , Chief Financial , Modus Therapeutics , Nasdaq First North , Sepsis Care , United Kingdom Final Report , Nasdaq Stockholm , Rosetta Capital , European Studies , David Dible , Citigate Dewe , ஒன்றுபட்டது கிஂக்டம் , அடித்தளம் க்கு பால்டிக் , தலைமை நிதி , மோடஸ் சிகிச்சை , நாஸ்டாக் முதல் வடக்கு , ஒன்றுபட்டது கிஂக்டம் இறுதி அறிக்கை , நாஸ்டாக் ஸ்டாக்‌ஹோல்ம் , ரொசெட்டா மூலதனம் ,